Literature DB >> 25290782

Tum variants: immunogenic variants obtained by mutagen treatment of tumor cells.

T Boon1.   

Abstract

Mutagen treatment of mouse tumor cells produces at high frequency stable tumor cell variants that are rejected by syngeneic mice. As Thierry Boon discusses here, these 'tum-' variants express new surface antigens that can be recognized by cytolytic T lymphocytes. Tum- variants derived from spontaneous mouse tumors for which no immunogenicity had hitherto been demonstrated induce an immune protection against the parental tumor. Finally, he poses some interesting questions for future investigations.
Copyright © 1985. Published by Elsevier B.V.

Entities:  

Year:  1985        PMID： 25290782     DOI： 10.1016/0167-5699(85)90182-3

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  6 in total

1.  Induction of high-grade anti-tumor immunity by use of a recombinant H-2Kb/avian erythroblastosis virus erbB gene transfectant.

Authors:  L N Ding; K Isobe; T Yoshida; K Kawashima; I Nakashima
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 2.  Strategies for cytokine utilisation in tumor therapy.

Authors:  F Di Pierro; F Cavallo; F Pericle; S Bertini; M Giovarelli; G Forni
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 3.  Chemical xenogenization of experimental tumors.

Authors:  P Puccetti; L Romani; M C Fioretti
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Mutagen-induced Imm+ variants: the need for viable and cloned Imm+ variants for effective protection against a primary murine tumor and its metastases.

Authors:  A Sella; B Hunt; P Frost
Journal:  Clin Exp Metastasis       Date:  1989 Jan-Feb       Impact factor: 5.150

5.  Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts.

Authors:  P Siesjö; E Visse; M Lindvall; L Salford; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

6.  Characterization of the individual and cross-reactive antigens involved in the anti-tumor immunity induced by use of an H-2K-erbB recombinant gene transfectant.

Authors:  L N Ding; T Yoshida; K Isobe; S M Rahman; F Nagase; T Yokochi; K Kawashima; I Nakashima
Journal:  Jpn J Cancer Res       Date:  1991-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.